199 related articles for article (PubMed ID: 17467045)
1. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
2. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
Prat J; De Nictolis M
Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
[TBL] [Abstract][Full Text] [Related]
3. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
4. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
5. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma.
Lee KR; Castrillon DH; Nucci MR
Int J Gynecol Pathol; 2001 Oct; 20(4):329-34. PubMed ID: 11603215
[TBL] [Abstract][Full Text] [Related]
6. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
Seidman JD; Kurman RJ
Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
9. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.
Seidman JD; Kurman RJ
Am J Surg Pathol; 1996 Nov; 20(11):1331-45. PubMed ID: 8898837
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component.
Slomovitz BM; Caputo TA; Gretz HF; Economos K; Tortoriello DV; Schlosshauer PW; Baergen RN; Isacson C; Soslow RA
Am J Surg Pathol; 2002 May; 26(5):592-600. PubMed ID: 11979089
[TBL] [Abstract][Full Text] [Related]
11. Serous borderline tumors of the ovary.
Prat J
Adv Clin Path; 1997 Apr; 1(2):97-102. PubMed ID: 10352473
[TBL] [Abstract][Full Text] [Related]
12. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
13. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
[TBL] [Abstract][Full Text] [Related]
14. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns.
Eichhorn JH; Bell DA; Young RH; Scully RE
Am J Surg Pathol; 1999 Apr; 23(4):397-409. PubMed ID: 10199469
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
[TBL] [Abstract][Full Text] [Related]
16. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Stramazzotti D; Lucarini G; Biagini G
Gynecol Oncol; 1995 Feb; 56(2):169-74. PubMed ID: 7896180
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor expression is a common feature of ovarian borderline tumors.
Abu-Jawdeh GM; Jacobs TW; Niloff J; Cannistra SA
Gynecol Oncol; 1996 Feb; 60(2):301-7. PubMed ID: 8631556
[TBL] [Abstract][Full Text] [Related]
18. Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion).
Tavassoli FA
Mod Pathol; 1988 Nov; 1(6):407-14. PubMed ID: 2464824
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases.
Smith Sehdev AE; Sehdev PS; Kurman RJ
Am J Surg Pathol; 2003 Jun; 27(6):725-36. PubMed ID: 12766576
[TBL] [Abstract][Full Text] [Related]
20. [Ovarian serous borderline tumor: the prognostic relation to the pathologic features and management].
Zhou XR; Du XG
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):601-3, 637. PubMed ID: 7712874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
